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Use of a Combination of Approaches to Identify andValidate
RelevantTumor-Associated Antigens andTheir Corresponding
Autoantibodies in Ovarian Cancer Patients
Audrey Gagnon,1Jae-Hoon Kim,5 John O. Schorge,6 BinYe,4 Brian Liu,2 Kathleen Hasselblatt,1
William R.Welch,3 Christina A. Bandera,7 and Samuel C. Mok1
Abstract Purpose:Novel biomarkers are urgently needed to increase the sensitivity of CA125 for the early
detection of ovarian cancer. Indeed, it has been shown that as much as 20% of early-stage
patients donot express significant levels of this biomarker.Therefore, the possibility of using auto-
antibodies directed against tumor-associated antigens as putative cancer markers is being more
examined. Indeed, many autoantibodies have recently been shown to correlate with cancer pa-
tient prognosis or to be suitable for detection of the disease.
Experimental Design: In this study, we have used a new approach involving the use of proteo-
mics, immunology, and ELISA methods to identify relevant autoantibodies in the plasma of ovar-
ian cancer patients. To do so, we developed an innovative technique called two-dimensional
differential gel electrophoresis analysis of immunoprecipitated tumor antigens.
Results:This strategy allowedus to successfully identify novel circulating autoantibodies direct-
ed against the S100A7 protein in the plasma of ovarian cancer patients. Further real-time reverse
transcription-PCRand immunohistochemical studies confirmed that the S100A7mRNA andpro-
teinwere highly expressed inovarian tumors but absent innormal andbenign tissues.Moreover, a
preliminary study involving138 patients confirmed that the plasma levels of anti-S100A7antibod-
ies are significantly elevated in early- and late-stage ovarian cancer patients compared with
healthy controls and with patients with benign gynecologic diseases.
Conclusions:This shows that our approach is a valuable tool to successfully identify autoanti-
bodies and tumor-associated antigens in cancer patients and that future research assessing their
putative clinical usefulness would be worthwhile.
Ovarian cancer is the leading cause of gynecologic cancer
death worldwide. In the United States, it is the eighth most
common cancer among women and the fifth most common
cause of cancer death, with about 20,180 new cases and 15,310
deaths expected in 2006 (1). However, the relatively asymp-
tomatic nature of early-stage disease and the lack of adequate
screening tests have resulted in the majority of cases presenting
with a late-stage disease (2). Currently, clinicians rely on a
combination of serum CA125 levels and imaging to diagnose
ovarian cancer in suspected patients and monitor treatment
response. However, due to its low sensitivity, the currently used
test to quantify the CA125 serum marker is not adequate for
early detection (3). Indeed, up to 20% of ovarian cancers fail to
express significant levels of the maker (4). Thus, there is an
urgent need for new ovarian cancer biomarkers that could
improve the sensitivity of ovarian cancer early detection.
The hunt for cancer biomarkers in the serum/plasma of
patients with cancer is based on the observation that some low-
molecular weight proteins that reflect the pathologic state of the
patients are shed into the bloodstream (5). Therefore, because
our immune system constantly surveys the body for ‘‘nonself’’
antigens, and generates a response against them, cancer patients
often mount a humoral response to autologous tumor-
associated antigens (TAAs; refs. 5, 6). Consequently, autoanti-
bodies have recently emerged as promising biomarkers for the
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detection of cancer (7). Moreover, autoantibodies directed
against certain TAAs have been reported in patients with a
variety of cancers, such as breast, head and neck, colon, kidney,
and melanoma, but not in healthy controls (8–10). In ovarian
cancer, we and others have previously reported that antibodies
directed against relevant antigens, such as EpCAM, and certain
heat shock proteins have a prognostic significance (11–14).
Additionally, the detection of serum antibodies against the
proapoptotic protein p53 was shown to predict subsequent
development of lung cancer, mesotheliomas, and lymphomas
(15). This suggests that circulating autoantibody levels could be
useful biomarkers for cancer (16). Thus, the detection of
autologous antibodies against relevant TAAs could be a
powerful tool for ovarian cancer detection and/or monitoring.
Here, we report the use of a newly developed two-dimensional
differential gel electrophoresis analysis of immunoprecipitated
tumor antigens (2D-DITA) technique to identify relevant TAAs
and their corresponding autoantibodies in patients with ovarian
cancer. We successfully identified significantly elevated levels of
S100A7 in ovarian cancer tissue and anti-S100A7 antibodies in
the plasma of ovarian cancer patients compared with healthy
controls.
Materials andMethods
Two-dimensional differential gel electrophoresis analysis of immuno-
precipitated tumor antigens. Malignant ovarian tissues weighingf800
mg were obtained from the three patients. Tissues were frozen in liquid
nitrogen and grounded to a fine powder using pestle and mortar. A
total of 5 AL of lysis buffer containing 1 TBS (pH 7.4), 1% Triton
X-100, and protease inhibitors (Sigma-Aldrich) were added and
incubated for 60 min at 4jC. The insoluble fraction was removed by
centrifuging 10 min at 4,500  g . The protein concentration was then
determined with the bicinchoninic acid assay reagent kit (Pierce
Biotechnology) according to the manufacturer’s instructions.
Plasma IgGs were purified from 1.0 mL of preoperative and
postoperative plasma samples obtained from the same patient using
the Montage antibody purification kit and spin columns (Millipore)
according to the manufacturer’s instructions. The protein concentration
was determined with the bicinchoninic acid protein assay reagent kit as
mentioned previously. Then, 4 mg from purified IgGs (preoperative and
postoperative) were desalted and concentrated to 50 AL using a
Vivaspin 15 (VivaScience). A buffer exchange was done readjusting the
final volume to 800 AL with 1 PBS (pH 7.4). Purified IgGs (4 mg)
were incubated overnight at 4jC with 500 AL of Protein G Sepharose 4
Fast Flow (GE Healthcare). Then, the beads were washed once with 1
PBS and twice with 0.2 mol/L triethanolamine (pH 8.2; Fluka
Biochemicals). Cross-linking was achieved by incubating the protein
G– immobilized antibody beads with 0.2 mol/L triethanolamine/
50 mmol/L dimethyl pimelimidate dihydrochloride (Sigma-Aldrich)
for 45 min. Beads were then washed once with 100 mmol/L
ethanolamine (pH 8.2) for 25 min followed by a 10-min wash in 1
TBS. Finally, the beads were washed once with 1 TBS containing 1%
Triton X-100 before incubation with the tissue lysate prepared from the
tumor tissue obtained from the same patient.
A total of 27 mg of protein lysate were added to the protein
G– immobilized IgG beads prepared from the preoperative and
postoperative serum samples. Both suspensions were incubated
overnight at 4jC on a rocking platform. The suspensions were then
washed twice with 1 TBS and once with 50 mmol/L Tris (pH 7.4). The
immunoprecipitated proteins were recovered by eluting with 500 AL of
two-dimensional sample buffer (Bio-Rad Laboratories) for 10 min at
room temperature. Insoluble proteins were removed by a 5-min
centrifugation at 7,000  g . The supernatants were then concentrated
to 100 AL as described previously. A further cleanup was done with the
Ready Prep 2-D Cleanup kit (Bio-Rad Laboratories) according to the
manufacturer’s instructions. The final pellet was resuspended in 30 AL
of two-dimensional sample buffer, and the pH of the supernatants was
adjusted to 8.5. CyDye3 and CyDye5 DIGE fluors (GE Healthcare) were
reconstituted to 1 mmol/L stock solutions with N,N-dimethylforma-
mide. Working dilutions for the fluors were prepared using 1.1 AL of
stock solution and 2.4 AL of N,N-dimethylformamide. Cy3 and Cy5
working solutions (1.6 AL) were added to the immunoprecipitated
proteins from the preoperative and postoperative samples, respectively.
The labeling reactions were carried out at 4jC for 30 min in the dark.
The reactions were terminated by the addition of 1 AL of 10 mmol/L
lysine for 10 min. Both Cy3- and Cy5-labeled samples were combined,
and the final volume was readjusted to 185 AL with two-dimensional
sample buffer.
Two-dimensional gel electrophoresis on the labeled samples was
done as described (17). The gels (one per patient) were scanned on a
Molecular Image FX. The DeCyder software (GE Healthcare) was
used to match the spots between all gels, to quantify the intensity of
each spot, and to identify the ones that were significantly
differentially expressed of >3-fold between preoperative and postop-
erative samples. Two of spots that showed highest differential signals
were sent to the Harvard University/Dana-Farber Cancer Center
Proteomics Core (Boston, MA) for protein identification by tandem
mass spectrometry.
Cell lines and culture conditions. All cell lines and cultures were
maintained at 37jC in a humidified 5% CO2 incubator. They were
grown in a 1:1 ratio of Medium 199 and MCDB 105 (both from Sigma-
Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich)
and 1% penicillin (5,000 IU/mL)/streptomycin (5,000 Ag/mL; Invi-
trogen). The eight normal human ovarian surface epithelial cell (HOSE)
cultures used in this study were established by scraping the surface of
the ovary as described previously (18).
Tissue and serum samples. All tissues used in this immunohisto-
chemical study were collected from patients treated at the Brigham and
Women’s Hospital between 1992 and 2000 under protocols approved
by the Brigham and Women’s Human Subject Committee. All tissues
were collected from the primary ovarian sites from patients undergoing
surgery.
Preoperative plasma samples were collected from women with
ovarian cancer and benign gynecologic malignancies and from age-
matched healthy controls under the Institutional Review Board
approval of the parent institutions. All specimens were frozen at
-80jC until needed.
Laser-based microdissection. Tissues stored in Tissue-Tek OCT
medium at -80jC were sectioned at 7 Am in a cryostat (Leica). Sections
were laser microdissected with the DMLMD laser-dissecting microscope
(Leica). Morphologically normal ovarian epithelial cells and malignant
cells were isolated.
Real-time quantitative reverse transcription-PCR. Total RNA extrac-
tion (RNeasy Mini kit, Qiagen) and cDNA synthesis (High Capacity
cDNA Archive kit, Applied Biosystems) were done as described by the
manufacturers. mRNA was extracted from 8 HOSE cell lines and from
37 microdissected high-grade papillary serous ovarian tumors. Real-
time reverse transcription-PCR was done twice in triplicate using
Taqman primer sets for S100A7 and for the housekeeping gene
cyclophilin (both from Applied Biosystems). All the reactions were run
in an ABI 7300 (Applied Biosystems). The fold change was calculated
with the DDCt method as previously described (19).
Immunohistochemistry. Immunostaining for S100A7 was done on
53 paraffin-embedded tissue specimens (28 papillary serous,
5 mucinous, 6 clear cell, and 14 endometrioid) using a monoclonal
antibody directed against S100A7 (1:50; Abcam) and the DakoCyto-
mation Envision kit (Dako) according to the manufacturer’s protocol.
The tissue sections were scored according to the following: 0 = no
evidence of staining, 1 = light staining in cells, 2 = moderate staining in
cells, and 3 = strong staining in most cells.
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ELISA. Flat-bottom microtiter plates (Fisher Scientific) were
coated overnight at 4jC with 0.10 Ag of purified recombinant
S100A7 protein (Abnova) diluted in 0.05 mol/L carbonate buffer
(pH 9.7). Then, the plates were washed thrice with PBS-Tween
20 and blocked for 30 min at 37jC in PBS + 5% bovine serum
albumin. The plates were washed thrice in PBS-Tween 20 and
incubated 2 h with patient serum samples diluted 1:100 in blocking
solution. After three washes in PBS-Tween 20, the plates were
incubated for 2 h with a horseradish peroxidase– conjugated
goat anti-human IgG diluted 1:5,000 in blocking solution (Chem-
icon). The plates were washed six times with PBS-Tween 20 and
incubated 30 min in the dark with 100 AL of 3,3¶,5,5¶-tetramethyl-
benzidine substrate solution (Pierce Biotechnology). The reactions
were stopped by the addition of 100 AL of 0.45 mol/L H2SO4, and
the absorbance was read at 450 nm on a plate reader (Bio-Rad
Laboratories). Results are expressed as the mean absorbance of
triplicate wells after subtraction of background value. The negative
controls were conducted by eliminating the purified S100A7 protein,
the patient serum, the secondary antibody, or the substrate for
development.
Statistical analysis. A nonparametric Mann-Whitney U test was
used to assess the statistical significance of the S100A7 mRNA
expression difference between normal HOSE cells and microdissected
ovarian cancer tissues and S100A7 autoantibody levels between
normal individuals and different cancer groups. A Kruskal-Wallis test
was used to assess the significance of the S100A7 levels in tissues
between histologic types, and a Mann-Whitney test was used to
compare the levels of S100A7 staining in normal versus malignant
tissues.
Results
To identify autoantibodies directed against relevant ovarian
TAAs, we did 2D-DITA on three pairs of plasma samples
collected from the same patients before surgery and 1 month
after the last cycle of chemotherapy. We hypothesized that
lower levels of autoantibodies against TAAs are found in
patients undergoing surgery or tumor-shrinking treatments.
Lower levels of autoantibodies in the postoperative plasma
samples compared with the preoperative samples should pull
down smaller amount of TAAs. Subsequent Cy3-labeled TAAs
pull down by the preoperative plasma samples and Cy5-labeled
TAAs pull down by the postoperative samples were resolved by
two-dimensional electrophoresis (Fig. 1). The two spots (TAAs)
that showed the highest differential signals were cut out and
sent for protein identification by tandem mass spectrometry
(Fig. 2).
After mass spectrometry analysis, one spot was identified as
being the HTRA2 protein, which is a 49-kDa serine protease that
shows proteolytic activity against h-casein and promotes and
induces cell death (20). The other spot was identified as S100A7,
which is a 11-kDa protein expressed by a wide variety of cells
and is involved in the regulation of cell cycle progression and
differentiation (21, 22). The S100A7 protein is overexpressed in
many cancers, such as breast, skin, bladder, and gastric cancer
(23–26). Therefore, due to its up-regulation in many cancers,
and to its chemotactic properties for immune cells, we chose to
characterize its autoantibody levels in more detail.
To validate the data obtained with our 2D-DITA technology,
we used quantitative real-time reverse transcription-PCR to
assess whether the S100A7 mRNA was overexpressed in ovarian
cancer tissues and in normal HOSE cells. We used cDNAs from
8 HOSE cell samples and 37 microdissected high-grade
Fig. 1. A, schematic representation of the 2D-DITA technology. Presurgery
and postsurgery plasma IgGs were isolated and cross-linked to beads. An
immunoprecipitation ofTAAs was then done using a tumor lysate from the same
patient. Both samples were labeled either with Cy3 or Cy5 and combined. B, the
combined presurgery and postsurgeryTAAs were resolved by two-dimensional
electrophoresis. Green spots, proteins down-regulated in the postoperative sample;
red spots, proteins down-regulated in the preoperative sample; yellow spots,
proteins that are present in both samples. One gel was run per patient.TheDeCyder
software was used to analyze the protein spot data in the three gels. Protein
identificationwas done on two spots that were significantly differentially expressed
in all three patients.
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papillary serous ovarian carcinomas. As shown in Fig. 3, the
mRNA levels of S100A7 are significantly higher (P < 0.001) in
most papillary serous tissues, whereas it is nearly absent in all
HOSE cells examined.
Immunohistochemistry was also done on 53 ovarian cancer
tissues (Fig. 4; Table 1A) and confirmed that the S100A7 protein
was, indeed, overexpressed in cancerous tissues compared with
normal (P = 0.003). Moreover, the up-regulation is not restricted
to papillary serous carcinoma but is also present in mucinous,
clear cell, and endometrioid ovarian cancers. Indeed, the levels
of S100A7 protein are significantly elevated in nonserous
ovarian cancers (P = 0.038). Interestingly, the protein expression
levels are not significantly different between early- and late-stage
disease (P = 0.95) or between low- and high-grade disease
(P = 0.75). This suggests that the up-regulation of S100A7may be
an early event in the pathogenesis of ovarian cancer, and the
Fig. 2. Identification of peptide fragments of human HTRA2 and S100A7 by liquid chromatography-tandemmass spectrometry. A and D, mass spectrum of the
SQYNFIADVVEK and KGTNYLADVFEK of human HTRA2 and S100A7, respectively. Fragmentations in the spectrum represent mainly single-event preferential cleavage of
the peptide bonds resulting in the sequence recorded from both NH2 and COOH termini (b- and y-type ions, respectively). B and E, peptides of HTRA2 and S100A7
identified from the tumor tissue lysates, respectively.C and F, sequence of humanHTRA2 (Swiss-Port database no. O43464) and S100A7 (Swiss-Port database no. P31151),
respectively, and the matched sequences are highlighted in red.
Fig. 3. Relative quantificationof the
S100A7 mRNA in 8 normal ovarian surface
epithelialcell samples and37microdissected
ovarian cancer tissue samples. Each value
was expressed as themean of duplicate.
The reference sample was HOSE2228,
whichwas considered to have a value of1.
Fold change was presented in log scale.
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patients could mount an immune response to it very early in the
progression of the disease. Furthermore, due to its secreted
nature, the up-regulation of S100A7 in the tumormay trigger the
development of antibodies against itself in these patients. Thus,
the detection of autoantibodies directed against this proteinmay
possibly be useful as ovarian cancer markers in all four subtypes
of ovarian carcinomas.
To confirm the up-regulation of anti-S100A7 antibodies in
ovarian cancer patients, we developed an ELISA assay and
quantified them in the plasma of 138 ovarian cancer patients
and healthy controls (11 benign gynecologic disease, 23
early-stage cancer, 69 late-stage cancer, and 35 age-matched
healthy controls; Table 1B). A nonparametric Mann-Whitney
U test shows that there is a significant difference between the
levels of autoantibodies directed against S100A7 in early- and
late-stage ovarian cancer patients compared with healthy
controls (P = 0.05 and P < 0.001, respectively; Fig. 5).
However, the levels of autoantibodies did not show
significant difference among different histologic subtypes of
ovarian cancer (P = 0.627). Notably, there is no significant
difference between healthy controls and patients with benign
gynecologic malignancies (P = 0.07). Moreover, patients with
other gynecologic cancers, such as uterine and cervical, did
not have elevated levels of anti-S100A7 antibodies, arguing
that this biomarker is specific to ovarian cancer (data not
shown).
Discussion
Recent studies showed that circulating autoantibodies
recognizing relevant TAAs can be detected in cancer patients,
suggesting that autoantibody-based tests may be used to
differentiate cancer patient sera from normal donor sera
(27–32). To identify relevant TAAs, we chose to compare the
levels of antibodies between preoperative and postoperative
plasma samples from the same patients. This choice was based
on the hypothesis that constant stimulation of the immune
system by TAAs is necessary to maintain a high level of
autoantibodies. Therefore, surgically removing the tumor
would prevent such stimulation. Thus, lower levels of autoanti-
bodies are found in patients undergoing surgery or tumor-
shrinking treatments (33). In fact, studies showed that anti-p53
antibodies decrease during cancer treatment. Therefore, lower
levels of our autoantibodies should be found in the postoper-
ative samples compared with the preoperative samples and they
are likely to recognize TAAs (34).
Fig. 4. Immunohistochemical
staining of the S100A7 protein in a
serous adenocarcinoma (A), an
endometrioid adenocarcinoma (B), a clear
cell adenocarcinoma (C), a mucinous
adenocarcinoma (D), a normal ovary (E),
and a benign ovarian cyst (F). Bar, 50 Am.
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Using an innovative proteomic technique, which allows the
simultaneous identification of autoantibodies and their
corresponding TAAs, we identified elevated levels of antibodies
directed against a protein called S100A7 in the plasma of
ovarian cancer patients but not in healthy controls. S100A7 is a
small, secreted, calcium-binding protein of the S100 protein
family that was originally identified as one of the most
abundant proteins in psoriatic keratinocytes (35). Further
studies have shown that its expression is elevated in premalig-
nant and squamous carcinoma of the bladder as well as in
primary invasive breast tumors (25, 36–38). This suggests that
the overexpression of the S100A7 protein may be an early event
in tumorigenesis. Furthermore, our studies showed significantly
higher levels of S100A7 protein expression in both early- and
late-stage ovarian cancer compared with benign and normal
ovarian tissue (Table 1). This suggests that increased S100A7
expression may be an early event in ovarian pathogenesis and
that its autoantibodies may thus be a potential target for
detecting the disease in its early stages.
No elevation of autoantibody levels against S100A7 has been
previously described. However, due to its secreted nature,
S100A7 has already been shown to act as a chemotactic factor
for CD4+ lymphocytes and neutrophils in the skin (39).
Moreover, the S100A7 protein levels are associated with
increased inflammatory cell infiltrates across all types of invasive
breast tumors (38). This shows that S100A7 is an immune cell
chemoattractant and that it induces an immune response in
breast cancer patients. Thus, this couldwell be the case in ovarian
cancer and may perhaps explain the presence of high levels of
anti-S100A7 antibodies seen in the plasma of these patients.
Our preliminary study confirmed the presence of elevated
S100A7 autoantibody levels in the plasma of ovarian cancer
patients. We also showed significantly higher autoantibody
levels in patients with both early- and late-stage ovarian cancer
compared with patients with benign gynecologic diseases or
healthy controls. Furthermore, even if the S100A7 protein levels
were significantly higher in the nonserous subtypes, we did not
find any significant difference in autoantibody levels among the
different histologic types. This suggests that the immunogenicity
of the S100A7 protein may be altered or increased by
posttranslational modifications such as glycosylation in the
different subtypes. Indeed, protein glycosylation is mechanisti-
cally important in the pathogenesis of autoimmune diseases
(40) and this may well be the case for cancer. Therefore, the
immune response generated by a patient against a specific
antigen could vary considerably. This still shows that S100A7 can
trigger a humoral immune response in patients with any subtype
of ovarian cancer and that the autoantibody levels generated by
this response are significantly higher than in healthy controls.
Moreover, because the anti-S100A7 antibody levels are
significantly elevated in all subtypes of ovarian cancer, they
may be useful biomarkers to improve the poor detection
sensitivity of the CA125 marker for nonserous ovarian cancer.
Indeed, CA125 serum levels are significantly lower in mucin-
ous, clear cell, and endometrioid ovarian cancer patients (2).
Table 1A. Differential expression of S100A7 in normal and malignant ovarian tissues
No. patients Mean (95% confidence interval) P
Normal/cancer
Normal 5 0.2 (-0.14 to 0.54) 0.003*
Cancer 53 1.64 (1.35-1.91)
Histologic types
Serous 29 1.29 (0.91-1.68) 0.038c
Mucinous 5 2.5 (1.11-3.89)
Endometrioid 14 1.71 (1.19-2.24)
Clear cell 5 2.2 (1.49-2.91)
Grade
Low (grade 1) 20 1.65 (1.12-2.17) 0.75
High (grade 2 and 3) 33 1.58 (1.23-1.92)
FIGO stage
I/II 27 1.65 (1.19-2.11) 0.95
III/IV 26 1.56 (1.2-1.92)
Abbreviation: FIGO, International Federation of Gynecologists and Obstetricians.
*Statistically significant by Mann-Whitney test.
cStatistically significant by Kruskal-Wallis test among groups.
Fig. 5. Box plot analysis of S100A7 autoantibody levels in healthy controls,
patients with benign gynecologic disease, and early- and late-stage ovarian cancer
patients.
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CA125 levels are available in all the cases that we screened
(data not shown). However, both sensitivity and specificity
estimates for ovarian cancer detection are not improved using
either anti-S100A7 alone or in combination with CA125, which
is likely due to the small sample size.
In conclusion, we used a novel approach to identify
autoantibodies directed against relevant TAAs in the plasma
of ovarian cancer patients. Our preliminary study found that
anti-S100A7 antibodies are significantly elevated in the plasma
of ovarian cancer patients compared with controls and with
patients with benign gynecologic diseases. We have confirmed
that the S100A7 protein and mRNA are overexpressed in all
four histologic types of ovarian cancer tissues. Our results
suggest that further studies using a larger sample size to
evaluate whether anti-S100A7 antibodies alone or in combi-
nation with other autoantibodies, such as EpCAM autoanti-
bodies (11), or other protein biomarkers can be used as
diagnostic markers for ovarian cancer screening are warranted.
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Table 1B. Characteristics of ovarian cancer patients used in the quantification of plasma anti-S100A7
antibodies
No. patients Mean antibody level (95% confidence interval) P
Normal/cancer
Normal 35 0.19 (0.154-0.226) 0.001*
Benign 11 0.221 (0.169-0.274)
Cancer 92 0.277 (0.25-0.304)
Histologic types
Serous 60 0.28 (0.244-0.316) 0.627
Mucinous 10 0.211 (0.141-0.283)
Endometrioid 10 0.272 (0.235-0.309)
Clear cell 12 0.281 (0.197-0.0365)
Stage
Early 23 0.227 (0.192-0.256) 0.03*
Late 69 0.294 (0.261-0.328)
*Statistically significant by Mann-Whitney test.
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